Share price · BMRN
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
See what was announced around each unusual move
Research flags the days this stock moved far more than its sector fund, lists the news, filings and earnings dated around each one, and shows how much of its unusual movement fell on each asset's announcements.
Assets
(10 total)
| Target & Modality | |||
|---|---|---|---|
Cerliponase alfa(BRINEURA) | Approved | —Protein / enzyme therapeutic | Neuronal Ceroid Lipofuscinosis Type 2 |
Elosulfase alfa(VIMIZIM) | Approved | —Protein / enzyme therapeutic | Mucopolysaccharidosis Type IVA |
Galsulfase(NAGLAZYME) | Approved | —Protein / enzyme therapeutic | Mucopolysaccharidosis Type VI |
Laronidase(ALDURAZYME) | Approved | —Protein / enzyme therapeutic | Mucopolysaccharidosis Type I |
Migalastat(Galafold) | Approved | Alpha-galactosidase A (GLA / α-Gal A)Small molecule | Fabry Disease |
Pegvaliase(PALYNZIQ) | Approved | —Protein / enzyme therapeutic | Phenylketonuria |
Vosoritide(VOXZOGO) | Approved | —Peptide | AchondroplasiaHypochondroplasia |
| Phase 3 | ENPP1 (ectonucleotide pyrophosphatase/phosphodiesterase 1)Protein / enzyme therapeutic | Chronic Kidney Disease | |
| Phase 2/3 | —Peptide | Achondroplasia | |
| Phase 1/2 | —RNA / oligonucleotide | Duchenne Muscular Dystrophy |
Upcoming events
Unlock the company readout calendar
Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.
Financial reports
Unlock sourced financial history
Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.
Insider transactions
Unlock insider transactions
Research includes SEC Form 4 insider transactions: filed buys, sells, awards and exercises linked to the underlying filings.
Institutional holders
Unlock institutional holders
Research includes quarterly SEC 13F institutional ownership: top holders, aggregate positions and quarter-over-quarter context.